Equity Overview
Price & Market Data
Price: $136.1
Daily Change: -$0.86 / 0.63%
Range: $134.9 - $138.0
Market Cap: $3,932,535,040
Volume: 338,560
Performance Metrics
1 Week: 8.55%
1 Month: -0.79%
3 Months: -25.94%
6 Months: -27.47%
1 Year: -18.82%
YTD: -13.14%
Company Details
Employees: 275
Sector: Health technology
Industry: Biotechnology
Country: United States
Details
Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, manufactures, and commercializes genetic medicines to treat diseases with high unmet medical needs in the United States. The company commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB). It also develops KB105, which is in Phase 1/2 clinical trials for treating patients with deficient autosomal recessive congenital ichthyosis; KB104 for treating netherton syndrome; KB407 that is in Phase 1 clinical trials for treating cystic fibrosis; KB707 that is in Phase 1/2 clinical trials for the treatment of anti-PD-1 relapsed/refractory; KB408, which is in Phase 1 clinical trials for treating Alpha-1 antitrypsin deficiency; and KB301 that is in Phase 2 clinical trials for treating aesthetic skin conditions, as well as in open label study with ophthalmic B-VEC for treating for ocular complications of deb. Krystal Biotech, Inc. was founded in 2016 and is headquartered in Pittsburgh, Pennsylvania.